BIOMARKER:

IFNG gene signature overexpression

B | Sensitive

C3 | Sensitive

B | Resistant

C3 | Resistant

Show legend

Drug categories

Immune Checkpoint Inhibitors

Immunotherapy

CD Protein Inhibitors

Epigenetics

Melanoma

Urothelial Cancer

Renal Cell Carcinoma

Pancreatic Cancer

Lymphoma

Head and Neck Cancer

Cervical Cancer

nivolumab + BMS-986205

IFNG gene signature overexpression|Melanoma|nivolumab + BMS-986205

IFNG gene signature overexpression|Urothelial Cancer|nivolumab + BMS-986205

IFNG gene signature overexpression|Renal Cell Carcinoma|nivolumab + BMS-986205

IFNG gene signature overexpression|Pancreatic Cancer|nivolumab + BMS-986205

IFNG gene signature overexpression|Lymphoma|nivolumab + BMS-986205

IFNG gene signature overexpression|Head and Neck Cancer|nivolumab + BMS-986205

IFNG gene signature overexpression|Cervical Cancer|nivolumab + BMS-986205

ipilimumab

IFNG gene signature overexpression|Melanoma|ipilimumab

nivolumab + 4SC-202

IFNG gene signature overexpression|Melanoma|nivolumab + 4SC-202

Immunotherapy

IFNG gene signature overexpression|Melanoma|Immunotherapy